Marco Meglio

Part B of the 2-part study will have patients previously on placebo receive SRP-9001 for an additional 52 weeks.

After being originally approved as a generic medication in 1996, a new transdermal formulation of donepezil is expected to be available for patients with Alzheimer disease in the fall of 2022.

Individuals on ravulizumab demonstrated statistically significant changes in the primary end point of MG-ADL and in secondary end points such as Quantitative Myasthenia Gravis total score.

At 97 weeks, avalglucosidase alfa showed continued benefit on measures such as forced vital capacity and 6-minute walk test distance and was successful for patients who switched off algucosidase alfa.

At months 6, 9, and 12 of treatment with daridorexant—which was recently FDA-approved for insomnia—patients improved on several sleep measures, including subjective total sleep time and daytime functioning.

Most of the 52 cognitive resilience proteins were found to be specific for cognitive decline and about 30% may provide resilience for both cognitive and noncognitive AD phenotypes.

Patients with chronic migraine on 60-mg once-daily and 30-mg twice-daily atogepant demonstrated reductions of 6.88 and 7.46 monthly migraine days, respectively, over a 12-week period.

In the EVOKE study (NCT02924129), the spinal cord stimulation system demonstrated superior pain relief compared to open-loop SCS at 12 months with no increase in pain medication.

Infection-related epilepsy etiology, experiencing multiple types of seizures, and cognitive impairment were independent influencing factors on perampanel use retention.

The staff neurologist and medical director of the Barlo Multiple Sclerosis Program at St Michaels Hospital provided insight on the use of biomarkers to improve management of RIS and uncover more as it relates to MS.

More than half of the patients with episodic migraine considered the likelihood of migraine on day 1 postdosing to be as important as the reduction in migraines in the days to follow.

Factors such as fear of negative consequences, attention and anticipation, and fear-avoidances were identified using the newly developed Fear of Attacks in Migraine Inventory questionnaire, which may have use in clinical settings.

Mobile stroke units led to a higher proportion of intravenous thrombolysis among patients with acute ischemic stroke, of whom up to one-third were treated within 60 minutes of symptom onset.

A third dose enhanced the number of responders to all variants and significantly increased CD8 T-cell responses, but the frequencies of Omicron-specific CD8 T-cells remained 70% of the responses specific to the vaccine strain.

Nine of 15 tested patients in the intrathecal stem cell group had a reduction of more than 50% in neurofilament light levels, compared with only 1 of 15 in the placebo group.

In a pilot study in late-onset Pompe disease, patients demonstrated improvements in leg extensor, flexor strength, and maximum inspiratory pressure following resistance training.

Those with a history of status epilepticus, one of the identified factors associated with modified Atkins diet initiation, could be a target population for which to initiate this approach early.

The two investigational agents from 4D Pharma have both been shown in preclinical studies to reduce neuroinflammation and to protect neurons from oxidative stress-induced death.

The assistant professor of neurology at the University of Pennsylvania provided insight on a new way to accurately predict chronic active lesion evolution from newly developing MS lesions using 7T MRI.

Most trials that reported on MS-related fatigue measured its change from baseline and whether that change was statistically significant.

Regardless of prophylactic or therapeutic paradigms, treatment with evobrutinib resulted in significantly reduced disease severity and improvement of immunopathological parameters of MS disease.

In recognition of Rare Disease Day, the NeurologyLive® team offered an extensive update on the state of care and treatment for a wide range of rare neurological diseases, including Kleine-Levin syndrome, amyotrophic lateral sclerosis, cerebral palsy, Lennox-Gastaut syndrome, and more.

Using a diagnostic threshold of at least 1 paramagnetic rim lesion, MS was identified with a sensitivity of 80% and specificity of 88%, which increased to 95% after excluding patients with RIS and CIS.

At the 12- and 24-week time points, patients in both diet groups demonstrated statistically significant differences in total cholesterol, low-density lipoprotein, body weight, and body mass index.

For patients who remained on 60-mg tolebrutinib through Part B of the study, the number of new Gadolinium-enhancing lesions and new/enlarging T2 lesions remained low.

There were no statistically significant differences in infusion-related reactions among patients with multiple sclerosis who tested positive or negative for treatment-emergent antidrug antibodies.

After 12 months of treatment, the 2 disease-modifying therapies were comparable in efficacy, with less treatment switching and discontinuation in cladribine-treated patients.

After Rapid LVO installation, CTA to groin puncture time decreased and 90-day clinical outcomes, expressed using modified Rankin Scale, were improved.

The assistant director of the Allegheny Headache Center provided context on a recently created headache registry and the need to prioritize treatment outcomes that matter to patients.

Investigators concluded that despite the linear relation between plasma concentration and dose, monitoring of fenfluramine is clinically relevant due to its high interpatient pharmacokinetic variability.